Cardiac involvement with amyloidosis: Mechanisms of disease, diagnosis and management

Connecticut Medicine

Volumn 75, Issue 10, 2011, Pages 581-590

  Marcu, Constantin B ^a   Niessen, Hans W ^b   Beek, Aernout M ^a   Brouwer, Wessel P ^a   Robbers, Lourens F ^a   Van Rossum, Albert C ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOIDOSIS; ARTICLE; CARDIOMYOPATHY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ELECTROCARDIOGRAPHY; ELECTRON MICROSCOPY; HEART MUSCLE; HUMAN; PATHOLOGY; PROGNOSIS; SUDDEN DEATH;

AMYLOIDOSIS; CARDIOMYOPATHIES; DEATH, SUDDEN, CARDIAC; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ELECTROCARDIOGRAPHY; HUMANS; MICROSCOPY, ELECTRON; MYOCARDIUM; PROGNOSIS;

EID: 82455221061     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Kyle RA: Amyloidosis: A convoluted story. Brit J Haematol 2001; 114(3):529-38.
2. Cohen AS, Calkins E: Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 1959; 183(4669):1202-3.
3. Merlini G, Westermark P: The systemic amyloidoses: Clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Int Med 2004; 255(2):159-78. (Pubitemid 38241361)
4. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349(6):583-96. (Pubitemid 36951371)
5. Cathcart ES, Comerfor FR, Cohen AS: Immunologic studies on a protein extracted from human secondary amyloid. N Engl J Med 1965; 273(3):143
6. Westermark P, Benson MD, Buxbaum JN, et al.: A primer of amyloid nomenclature. Amyloid 2007; 14(3):179-83. (Pubitemid 47262691)
7. Rapezzi C, Merlini G, Quarta CC, et al.: Systemic cardiac amyloidoses: Disease profiles and clinical courses of the three main types. Circulation 2009; 120(13):1203-12.
8. Dubrey SW, Cha K, Skinner M, et al.: Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distincdy different clinical outcomes. Heart 1997; 78(1):74-82. (Pubitemid 27346885)
9. Ng B, Connors LH, Davidoff R, et al.: Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 2005; 165(12):1425-9. (Pubitemid 40973426)
10. Brenner DA, Jain M, Pimentel DR, et al.: Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94(8):1008-10. (Pubitemid 38579694)
11. Shi J, Guan J, Jiang B, et al.: Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38+| MAPK pathway. Proc Natl Acad Sci 2010;107(9):4188-93.
12. Dubrey SW, Cha K, Anderson J, et al.: The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM1998; 91(2):141-57. (Pubitemid 28102667)
13. Smith RR, Hutchins GM: Ischemic heart disease secondary to amyloidosis of intramyocardial aiteries.Am J Cardiol 1979; 44(3):413-7. (Pubitemid 10233857)
14. Smith TJ, Kyle RA, Lie JT: Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 1984; 59(8):547-55. (Pubitemid 14061503)
15. Mueller PS, Edwards WD, Gertz MA: Symptomaticischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000; 109(3):181-8.
16. Neben-Wittich MA, Wittich CM, Mueller PS, et al.: Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J med 2005; 118(11):1287.
17. Wittich CM, Neben-Wittich MA, Mueller PS, et al.: Deposition of amyloid proteins in the epicardial coronary arteries of 58 patients with primary systemic amyloidosis. Cardiovasc Pathol2007; 16(2):75-8. (Pubitemid 46274406)
18. ReisingerJ, Dubrey SW, Lavalley M, et al.: Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 1997; 30(4):1046-51. (Pubitemid 27435899)
19. Plehn JF, Southworth J, Cornwell GG: Atrial systolic failure in primary amyloidosis. N Engl J Med 1992; 327(22):1570-3.
20. Dubrey S, Pollak A, Skinner M, Falk RH: Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: Evidence for atrial electromechanical dissociation. Brit Heart J1995; 74(5):541-4.
21. Feng D, Syed IS, Martinez M, et al.: Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009; 119(18):2490-7.
22. Gertz MA, Lacy MQ, Dispenzieri A: Amyloidosis. Hematol Oncol Clin North Am 1999; 13(6):1211-33, ix. (Pubitemid 30017396)
23. Falk RH, Comenzo RL, Skinner M: The systemic amyloidoses. N Engl J Med 1997; 337:898-909. (Pubitemid 27408573)
24. Falk RH, Skinner M: The systemic amyloidoses: An overview. Adv Intern Med 2000; 45:107-37.
25. Kyle RA, Gertz MA, Greipp PR, et al.: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336(17):1202-7. (Pubitemid 27183649)
26. Kyle RA, Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32(1):45-59. (Pubitemid 24370135)
27. Connors LH, Lim A, Prokaeva T, et al.: Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10(3):160-84. (Pubitemid 37372400)
28. Rapezzi C, Riva L, Quarta CC, et al.: Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008; 15(1):40-8. (Pubitemid 351238493)
29. Jacobson DR, Pastore RD, Yaghoubian R, et al.: Variantsequence transthyretin (Isoleucine 122) in late-onset cardiac amyloidosis in Black Americans. N Engl J Med 1997; 336(7):466-73. (Pubitemid 27074357)
30. Connors LH, Prokaeva T, Lim A, et al.: Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am HeartJ2009; 158(4):607-14.
31. Falk RH:The neglected entity of familial cardiac amyloidosis in African Americans. Ethn Dis 2002; 12(1):141-3.
32. Westermark P, Sletten K, Johansson B, Cornwell GG: Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Set U S Am 1990; 87(7):2843-5.
33. Tanskanen M, Peuralinna T, Polvikoski T, et al.: Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2ΣÇÉmacroglobulin and tau: A populationrΣ ÇÉbased autopsy study. Ann Med 2008; 40(3):232-9. (Pubitemid 351482541)
34. Cornwell GG, III, Murdoch WL, Kyle RA, et al.: Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983; 75(4):618-23. (Pubitemid 13012155)
35. Kyle R A, Spittell PC, Gertz MA, et al.:Thepremortemrecognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996; 101(4):395-400. (Pubitemid 26392857)
36. Kawamura S, Takahashi M, Ishihara T, Uchino F: Incidence and distribution of isolated atrial amyloid: Histologic and immunohistochemical studies of 100 aging hearts. PatholInt 1995; 45(5):335-42.
37. Steiner I: The prevalence of isolated atrial amyloid. J Pathol 1987; 153(4):395-8.
38. Ariyarajah V, Steiner I, Hajkova P, et al.: The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens. Cardiology 2009; 113(2):132-7.
39. Steiner I, Hajkova P: Patterns of isolated atrial amyloid: A study of 100 hearts on autopsy. Cardiovasc Pathol 2006; 15(5):287-90. (Pubitemid 44345233)
40. Gejyo F, Yamada T, Odani S, et al.: A new form of amyloid protein associated with chronic hemodialysis was identified as [beta]2-microglobulin. Biochem Biophys Res Commun 1985; 129(3):701-6. (Pubitemid 15243930)
41. Drueke TB: Beta2 Microglobulin and amyloidosis. Nephrol Dial Transplant 2000; 15(suppl l):17-24.
42. Saito A, Gejyo F: Current clinical aspects of dialysis-related amyloidosis in chronic dialysis patients. Ther Apher Dial2006; 10(4):316-20. (Pubitemid 44154760)
43. Dubrey SW, Cha K, Simms RW, et al.: Electrocardiography and doppler echocardiography in secondary (AA) amyloidosis. AmJ Cardiol1996; 77(4):313-5. (Pubitemid 26059307)
44. Livneh A, Langevitz P: Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol 2000; 14(3):477-98.
45. Libbey CA, Skinner M, Cohen AS: Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med 1983; 143(8):1549-52. (Pubitemid 13033756)
46. Gertz MA, Grogan M, Kyle RA, Tajik AT: Endomyocardial biopsy-proven light chain amyloidosis (AL) without echocardiographic features of infiltrative cardiomyopathy. Am J Cardiol 1997; 80(1):93-5. (Pubitemid 27274590)
47. Kumar S, Dispenzieri A, Katzmann JA, et al.: Serum immunoglobulin free light-chain measurement inprimary amyloidosis: prognostic value and correlations with clinical features. Blood 2010; 116(24):5126-9.
48. Dispenzieri A.Lacy MQ, Katzmann JA, et al.: Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem-cell transplantation. Blood2006; 107(8):3378-83.
49. Murtagh B, Hammill SC, Gertz MA, et al.: Electrocardiographic findings in primary systemic amyloidosis and biopsyproven cardiac involvement. Am J Cardiol2005; 95(4):535-7. (Pubitemid 40247559)
50. Falk RH, Plehn JF, Deering T,et al.: Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 1987; 59(5):418-22. (Pubitemid 17032895)
51. Siqueira-Filho AG, Cunha CL, Tajik AJ, et al.: M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981; 63(1):188-96. (Pubitemid 11213350)
52. Patel AR, Dubrey SW, Mendes LA, et al.: Right ventricular dilation in primary amyloidosis: An independent predictor of survival. AmJ Cardiol 1997; 80(4):486-92. (Pubitemid 27371756)
53. Falk RH: Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112(13):2047-60.
54. Klein AL, Hade LK, Burstow DJ, et al.. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol1989; 13:1017-26. (Pubitemid 19091289)
55. Klein AL, Hade LK,Taliercio CP, et al.: Serial doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990;16(5):1135-41. (Pubitemid 20378463)
56. Klein AL, Hade LK, Taliercio CP,et al.: Prognostic significance of doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991; 83:808-16.
57. Koyama J, Falk RH: Prognostic significance of strain doppler imaging in light-chain amyloidosis. JACC: Cardiovasc Imaging 2010; 3(4):333-42.
58. Koyama J, Ray-Sequin PA, Davidoff R, Falk RH: Usefulness of pulsed tissue doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 2002; 89(9)1067-71. (Pubitemid 34462852)
59. Koyama J, Ray-Sequin PA, Falk RH: Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003; 107(19):2446-52. (Pubitemid 36605227)
60. Marcu CB, Beek AM, van Rossum AC: Clinical applications of cardiovascular magnetic resonance imaging. CMAJ 2006; 175(8):911-7. (Pubitemid 44622848)
61. Marcu CB, Nijveldt R, Beek AM, van Rossum AC: Delayed contrast enhancement magnetic resonance imaging for the assessment of cardiac disease. Heart Lung Circ2007; 16(2):70-8. (Pubitemid 46421764)
62. Maceira AM, Joshi J, Prasad SK, et al.: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111:195-202.
63. Maceira AM, Prasad SK, Hawkins PN, et al.: Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis.J Cardiovasc Magn Reson 2008; 10(1):54.
64. Ruberg FL, Appelbaum E, Davidoff R, et al.: Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009; 103(4):544-9.
65. Austin BA, Tang WH, Rodriguez ER, et al.: Delayed hyperenhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009; 2(12)1369-77.
66. Syed IS, Glockner JF, Feng D, et al.: Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC: Cardiovasc Imaging 2010; 3(2)155-64.
67. Sparrow P, Amirabadi A, Sussman MS, et al.: Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis. J Magn Reson Imaging 2009; 30(5):942-6.
68. Kribben A, Witzke O, Hillen U, et al.: Nephrogenic systemic fibrosis: Pathogenesis, diagnosis, andtherapy. and therepy. J Am Coll Cardiol 2009; 53(18)1621-8.
69. Glaudemans A, Slart R, Zeebregts C, et al.: Nuclear imaging in cardiac amyloidosis. Eur J Nuclear Med Mol Imaging 2009; 36(4):702-14.
70. Perugini E, Guidalotti PL, Salvi F, et al.: Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-Diphosphono-l,2- Propanodicarboxylic acid scintigraphy. JAm Coll Cardiol2005; 46(6)1076-84. (Pubitemid 41316518)
71. Rapezzi C, Quarta C, Guidalotti P, et al.: Usefulness and limitations of 99mTc-3,3-diphosphono-l,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nuclear Med Mollmaging 2011; 38(3):470-8.
72. Nakata T, Shimamoto K, Yonekura S, et al.: Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: Detection with iodine-123-MIBG. J Nucl Med 1995; 36(6)1040-2.
73. Dispenzieri A, Kyle RA, Gertz MA, et al.: Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361(9371)1787-9. (Pubitemid 36638428)
74. Nordlinger M, Magnani B, Skinner M, Falk RH: Is elevated plasma B-Natriuretic peptide in amyloidosis simply a function of the presence of heart failure?Am J Cardiol 2005;96(7):982-4. (Pubitemid 41362524)
75. Palladini G, Lavatelli F, Russo P, et al.: Circulating amyloidogenic free light chains and serum N-terminai natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood2006; 107:3854-8. (Pubitemid 43726787)
76. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22(18):3751-7. (Pubitemid 41095215)
77. Rubinow A, Skinner M, Cohen AS: Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981; 63(6)1285-8. (Pubitemid 11120664)
78. Pollak A, Falk RH: Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993; 104(2):618-20. (Pubitemid 23229546)
79. Kristen AV, Dengler TJ, Hegenbart U, et al.: Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008; 5(2):235-40.
80. Dispenzieri A, Kyle RA, Lacy MQ, et al.: Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem-cell transplantation: A case-control study. Blood 2004; 103(10):3960-3. (Pubitemid 38596319)
81. Skinner M, Sanchorawala V, Seldin DC, et al.: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An eight-year study. Ann Intern Med 2004; 140(2):85-93.
82. Dispenzieri A, Lacy MQ, Zeldenrust SR.et al.:The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109(2):465-70. (Pubitemid 46105939)
83. Kastritis E, Wechalekar AD, Dimopoulos MA, et al.: Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol2010; 28(6)1031-7.
84. Dispenzieri A, Gertz MA, Kyle RA, et al.: Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem-cell transplantation. Blood 2004; 104(6)1881-7. (Pubitemid 39202301)
85. Gertz M, Lacy M, Dispenzieri A, et al.. Troponin T level as an exclusion criterion for stem-cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008; 49(1):36-41. (Pubitemid 351146880)
86. Kumar S, Dispenzieri A, Lacy MQ, et al.: Serum uric acid: Novel prognostic factor in primary systemic amyloidosis.Mavo Clin Proc 2008; 83(3):297-303.
87. Dubrey SW, Burke MM, Hawkins PN, Banner NR: Cardiac transplantation for amyloid heart disease:The United Kingdom expenence.J Heart Lung Transplant 2004; 23(10)1142-53. (Pubitemid 39346230)
88. Kpodonu J, Massad MG, Caines A, Geha AS: Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005; 24(11)1763-5. (Pubitemid 41641848)
89. Maurer MS, Raina A, Hesdorffer C, et al.: Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 2007; 83:539-45. (Pubitemid 46440239)
90. Yazaki M, Mitsuhashi S, Tokuda T, et al.: Progressive wildtype transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007; 7(1):235-42. (Pubitemid 44952878)
91. Stangou AJ, Heaton ND, Hawkins PN: Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med2005; 352(22):2356. (Pubitemid 40740565)